Diethylcarbamazine

Diethylcarbamazine

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	by mouth
ATC code	P02CB02 (WHO) QP52AH02 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name N,N-diethyl-4-methylpiperazine-1-carboxamide
Synonyms	N, N-diethyl-4-methyl-1-piperazine carboxamide
CAS Number	90-89-1 Y
PubChem CID	3052
DrugBank	DB00711 Y
ChemSpider	2944 Y
UNII	V867Q8X3ZD
KEGG	D07825 Y
ChEMBL	CHEMBL684 Y
ECHA InfoCard	100.001.840
Chemical and physical data
Formula	C10H21N3O
Molar mass	199.293 g/mol
3D model (Jmol)	Interactive image
SMILES C1CN(C)CCN1C(=O)N(CC)CC
InChI InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3 Y Key:RCKMWOKWVGPNJF-UHFFFAOYSA-N Y

Diethylcarbamazine (DEC) is a medication used in the treatment of filariasis including lymphatic filariasis, tropical pulmonary eosinophilia, and loiasis. It may also be used for prevention of loiasis in those at high risk. While it has been used for onchocerciasis (river blindness), invermectin is preferred. It is taken by mouth.

Common side effects itching, facial swelling, headaches, and feeling tired. Other side effects include vision loss and dizziness. It is a recommended treatment in pregnancy and appears to be safe for the baby. The World Health Organization; however, recommends until after pregnancy for treatment. It is made from piperazine.

Diethylcarbamazine was discovered in 1947. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is less than 0.01 USD per dose. It is not commercially available in the United States but can be gotten from the Center for Disease Control.

DEC is indicated for treatment of individual patients with certain filarial diseases. These diseases include: lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori; tropical pulmonary eosinophilia, and loiasis.